---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-011941"
form_type: "8-K"
ticker: "QCLS"
cik: "0001321834"
company_name: "Q/C TECHNOLOGIES, INC."
filed_at: "2023-04-12T23:59:59+00:00"
generated_at: "2026-06-17T02:57:30.109442+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MyMD doses 37 of 40 patients in Phase 2 trial of MYMD-1 for sarcopenia/frailty; no safety issues

## Summary
- Safety Review Committee confirms no safety/toxicity issues with first 30 patients; unanimous vote to escalate to final dose level.
- 37 of 40 total patients randomized and dosed across four cohorts; only 3 patients away from dosing final patient.
- Phase 2 double-blind, placebo-controlled study targets reduction of chronic inflammatory markers (IL-6, sTNFR-1) in patients aged 65+.
- No FDA-approved treatments currently exist for sarcopenia/frailty; aging disorders market estimated at $600B by 2025.
- Company planning early-stage trials for rheumatoid arthritis with MYMD-1.

## SEC filing metadata
- accession: 0001493152-23-011941
- form_type: 8-K
- ticker: QCLS
- cik: 0001321834
- company_name: Q/C TECHNOLOGIES, INC.
- filed_at: 2023-04-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321834/000149315223011941/0001493152-23-011941-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321834/000149315223011941/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-011941
- JSON: https://secwatch.observer/filing/0001493152-23-011941.json
- Plain text: https://secwatch.observer/filing/0001493152-23-011941.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.